Trial Profile
A Phase 1 Study of ABT 510 [ABT-510] and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs ABT 510 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 16 May 2012 Primary endpoint added as reported by ClinicalTrials.gov.
- 30 Jan 2008 New trial record.